Study of the TEM-1 Antibody, MORAb-004 (IND 103821), in Children With Recurrent or Refractory Solid Tumors

Trial Profile

Study of the TEM-1 Antibody, MORAb-004 (IND 103821), in Children With Recurrent or Refractory Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Feb 2016

At a glance

  • Drugs Ontuxizumab (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Morphotek
  • Most Recent Events

    • 29 May 2015 Primary endpoint has been met (MTD, defined as the maximum dose at which fewer than one-third of patients experience dose-limiting toxicities (DLT) graded according to the revised National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0) according to results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 29 May 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 29 May 2015 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top